Holen Sie sich die Stockscreener-App
27.51
0.26%
0.07
Handel nachbörslich:
27.48
-0.03
-0.11%
Schlusskurs vom Vortag:
$27.44
Offen:
$27.41
24-Stunden-Volumen:
7.05M
Relative Volume:
0.49
Marktkapitalisierung:
$6.42B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
52.69
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
-0.72%
1M Leistung:
-9.83%
6M Leistung:
+6.30%
1J Leistung:
-46.85%
1-Tages-Spanne:
$26.73
$27.63
1-Wochen-Bereich:
$26.73
$28.33
52-Wochen-Spanne:
$13.74
$65.30
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
27.51 | 6.42B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
18.26 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
37.09 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.19 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.97 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
497.11 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit - PR Newswire
Hims & Hers Stock Faces a Margin Test Just as Its Legal Troubles Mount. Here’s What Every Investors Need to Know. - TIKR.com
Kaplan Fox Urges Hims & Hers Health, Inc. (NYSE: HIMS) Investors to Contact the Firm Before the Deadline on November 2, 2026 - NewMediaWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers Health, Inc. (HIMS) And Encourages Shareholders to Connect - accessnewswire.com
Kaplan Fox Urges Hims & Hers Health, Inc. (NYSE: HIMS) Investors - The National Law Review
Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock DeclineInvestors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC - PR Newswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bronstein, Gewirtz & Grossman, LLC (HIMS) And Encourages Investors to Reach Out - ACCESS Newswire
Hims & Hers Health, Inc. (HIMS) Securities Fraud Class Action Lawsuit Filed; November 2, 2026, Lead Plaintiff Deadline - PR Newswire
JPMorgan Tweaks Hims & Hers Stock Outlook on Key Risk - TradingView
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders - The Daily Tribune News
DEADLINE ALERT for YSS, HIMS, UNCY, and PZZA: The Law - GlobeNewswire
HIMS Looks 38.5% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
HIMS Assumes Neutral Rating by JP Morgan -- Price Target Announced at $32 - GuruFocus
Hims & Hers Health faces class action over alleged website tracking - Top Class Actions
JPMorgan cautious on Hims & Hers on GLP-1 transition risk By Investing.com - Investing.com South Africa
Hims & Hers Health resumed at JP Morgan at neutral on GLP-1 compounding headwinds - Seeking Alpha
Price-Driven Insight from (HIMS) for Rule-Based Strategy - Stock Traders Daily
Analyst recommendations: Hims & Hers, Adobe, MongoDB… - marketscreener.com
Kaplan Fox Announces a Securities Class Action Filed Against Hims & Hers Health, Inc. (NYSE: HIMS)Lead Plaintiff Deadline is November 2, 2026 - NewMediaWire
HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - The Daily Tribune News
Hims & Hers Health, Inc. (HIMS) Stock Price & News - Syfe
Hims & Hers Health, Inc. (HIMS) Class Action Lawsuit Seeks - GlobeNewswire
ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire
Kaplan Fox Continues to Remind Hims & Hers Health, Inc. (NYSE: HIMS) Investors of the Lead Plaintiff Deadline on November 2, 2026 - NewMediaWire
Faruqi & Faruqi, LLP Urges Hims & Hers Health, Inc. (HIMS) Invest - The National Law Review
HIMS & HERS HEALTH, INC. INVESTORS WITH LOSSES HAVE UNTIL - GlobeNewswire
Portnoy Law Firm Announces Class Action on Behalf of Hims & Hers Health, Inc. Investors - GlobeNewswire
Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on November 2, 2026 Against Hims & Hers Health, Inc. (NYSE: HIMS) - newmediawire.com
Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Hims & Hers Health, Inc. (HIMS) And Encourages Shareholders to Reach Out - ACCESS Newswire
Hims & Hers Health (HIMS) Investors with Substantial Losses Have Opportunity to Lead Hims & Hers Class Action Lawsuit Before November 2, 2026 Deadline - PR Newswire
Deadline Alert: Hims & Hers Health, Inc. (HIMS) - GlobeNewswire
Hims & Hers Health, Inc. • Robinhood Token (HIMS) Preț Azi - Bybit
HIMS Class Action Reminder – Robbins LLP Reminds Investors - GlobeNewswire
Why Is Hims & Hers Health (HIMS) Down 7.7% Since Last Earnings Report? - Yahoo Finance
Hims & Hers Health Stock (HIMS) Opinions on Regulatory Scrutiny and AI Potential - Quiver Quantitative
Hims & Hers Health, Inc. • Robinhood Token (HIMS) Price Prediction for 2026 to 2031 - Bybit
Is FTC Lawsuit Altering The Investment Case For Hims Stock (HIMS)? - simplywall.st
Kaplan Fox Continues to Alert Investors of Hims & Hers Health, Inc. (NYSE: HIMS) to a Class Action Deadline on November 2, 2026 - NewMediaWire
Hims & Hers Health, Inc. Securities Fraud Class Action - GlobeNewswire
Hims & Hers Health, Inc. (HIMS) Gains As Market Dips: What You Should Know - Yahoo Finance
Kaplan Fox Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors Seeking Recovery to Contact the Firm Before November 2, 2026 - NewMediaWire
Hims & Hers stock: growth momentum versus margin pressure and a 20.6% fair value discount - Investing.com Canada
Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Kaplan Fox Encourages Wix.com Ltd. (NASDAQ: WIX) Investors with Significant Losses to Contact the Firm Before September 22, 2026 - GlobeNewswire Inc.
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire
HIMS & HERS HEALTH, INC. (HIMS) SHAREHOLDER ALERT Bernstein - GlobeNewswire
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - accessnewswire.com
Hims & Hers Health (NYSE: HIMS) Faces Securities Class Action After FTC Lawsuit Reveal Drives Stock Sharply Lower -- HBSS - PR Newswire
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.30%
1.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):